The Marketing Authorisation of Advanced Therapy Medicinal Products under the regulation of the European Union - HAL Accéder directement au contenu
Poster de conférence Année : 2023

The Marketing Authorisation of Advanced Therapy Medicinal Products under the regulation of the European Union

Résumé

Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based on genes, cells and tissues specifically regulated in the European Union (EU) from the entry into force of Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on ATMPs. Any company wishing to market ATMPs within the EU must hold a Marketing Authorisation (MA) issued by the European Commission under the “centralised procedure”, after a single application to the European Medicines Agency (EMA) and its scientific assessment by the Committee for Advanced Therapies. The purpose of the MA is to ensure high quality, safety and efficacy for ATMPs, with a positive risk-benefit balance, to be commercialised. The MA is valid in the EU Member States, Iceland, Norway and Liechtenstein for a five-years period. From the adoption of the EU regulation, 24 ATMPs have been granted a marketing authorisation in the EU and the European Commission decision is pending for another one. There has been a clear increase in approvals from 2018, and most approved ATMPs are gene therapy medicinal products. Almost half of them benefited from expediting pathways or regulatory support schemes for (innovative) medicines to be commercialised in the EU. Nevertheless, MA has been withdrawn or not renewed for 7 of them. This poster will present the European regulatory requirements and pathways for ATMPs to obtain marketing authorisation, and discuss the challenges of their commercialisation.
Fichier principal
Vignette du fichier
Poster - ISCT 2023 PARIS The marketing authorisation of advanced therapy medicinal product FINAL.pdf ( 9.85 Mo ) Télécharger
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

halshs-04290539, version 1 (16-11-2023)

Identifiants

  • HAL Id : halshs-04290539 , version 1

Citer

Aurélie Mahalatchimy, Luc-Sylvain Gilbert, Auxane Delage, Olivier Nègre. The Marketing Authorisation of Advanced Therapy Medicinal Products under the regulation of the European Union. International Society for Cell & Gene Therapy 2023 Annual Meeting, May 2023, Paris Palais des congrès, France. Abstract published in Cytotherapy, 25 (6 Supplement), pp.S160-S161, 2023. ⟨halshs-04290539⟩
45 Consultations
7 Téléchargements
Dernière date de mise à jour le 28/04/2024
comment ces indicateurs sont-ils produits

Partager

Gmail Facebook Twitter LinkedIn Plus